Search research articles
Contact Us
Filters
Showing results (21-30 of 32) with videos related to
Page
of 4
Sort By:
The Journal of Clinical Endocrinology and Metabolism
|
December 9, 2025
Patient-Reported Outcomes in Palopegteriparatide-Treated Adults with Hypoparathyroidism: PaTH Forward Trial Extension
Mishaela Rubin, Andrea Palermo, Tamara Vokes, et al.
Hormone Research in Paediatrics
|
March 6, 2025
Children with Growth Hormone Deficiency Treated with Lonapegsomatropin Demonstrated Sustained Height Improvements for up to 6 Years: enliGHten Trial Final Results
Aristides K Maniatis, Paul S Thornton, Ulhas M Nadgir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 2, 2013
Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer
Ignace B Vergote, Agustin Garcia, John Micha, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 1, 2017
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial
Chris Twelves, Javier Cortés, Joyce O'Shaughnessy, et al.
Breast Cancer Research and Treatment
|
September 9, 2017
Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial
Javier Cortés, Hope S Rugo, Ahmad Awada, et al.
The Lancet. Oncology
|
October 21, 2015
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial
Edith A Perez, Ahmad Awada, Joyce O'Shaughnessy, et al.
The Lancet. Oncology
|
October 8, 2013
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study
Ahmad Awada, Agustin A Garcia, Stephen Chan, et al.
Breast Cancer Research and Treatment
|
June 15, 2017
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial
Javier Cortés, Hope S Rugo, Ahmad Awada, et al.
Pulmonary Circulation
|
December 5, 2024
SOPRANO: Macitentan in patients with pulmonary hypertension following left ventricular assist device implantation
Robert P Frantz, Shashank S Desai, Gregory Ewald, et al.
Advances in Therapy
|
May 1, 2024
Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial
Lars Rejnmark, Elvira O Gosmanova, Aliya A Khan, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 32) with videos related to
Sort By:
Page
of 4
The Journal of Clinical Endocrinology and Metabolism
|
December 9, 2025
Patient-Reported Outcomes in Palopegteriparatide-Treated Adults with Hypoparathyroidism: PaTH Forward Trial Extension
Mishaela Rubin, Andrea Palermo, Tamara Vokes, et al.
Hormone Research in Paediatrics
|
March 6, 2025
Children with Growth Hormone Deficiency Treated with Lonapegsomatropin Demonstrated Sustained Height Improvements for up to 6 Years: enliGHten Trial Final Results
Aristides K Maniatis, Paul S Thornton, Ulhas M Nadgir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 2, 2013
Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer
Ignace B Vergote, Agustin Garcia, John Micha, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 1, 2017
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial
Chris Twelves, Javier Cortés, Joyce O'Shaughnessy, et al.
Breast Cancer Research and Treatment
|
September 9, 2017
Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial
Javier Cortés, Hope S Rugo, Ahmad Awada, et al.
The Lancet. Oncology
|
October 21, 2015
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial
Edith A Perez, Ahmad Awada, Joyce O'Shaughnessy, et al.
The Lancet. Oncology
|
October 8, 2013
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study
Ahmad Awada, Agustin A Garcia, Stephen Chan, et al.
Breast Cancer Research and Treatment
|
June 15, 2017
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial
Javier Cortés, Hope S Rugo, Ahmad Awada, et al.
Pulmonary Circulation
|
December 5, 2024
SOPRANO: Macitentan in patients with pulmonary hypertension following left ventricular assist device implantation
Robert P Frantz, Shashank S Desai, Gregory Ewald, et al.
Advances in Therapy
|
May 1, 2024
Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial
Lars Rejnmark, Elvira O Gosmanova, Aliya A Khan, et al.
Page
of 4